Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Crysvita (burosumab-twza) is a fibroblast growth factor 23 (FGF23)-blocking antibody. It is indicated for the treatment of:
It is a prescription biologic and must be used under the supervision of a qualified endocrinologist.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Crysvita (burosumab-twza) injection may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.
Crysvita (burosumab-twza injection) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Crysvita is not commercially marketed in India.
However, patients in India can legally access Crysvita through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of a specific patient for their personal treatment, under a valid prescription.
Crysvita received US FDA approval in 2018, ensuring full transparency throughout the process.
Crysvita can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) can source Crysvita from reliable global channels and facilitate supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Crysvita requires cold-chain handling throughout transit and must be kept refrigerated between 2°C to 8°C, in its original carton, until use. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For Crysvita cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access Crysvita through regulated import pathways, with delivery arranged to the treating hospital based on a valid endocrinologist's prescription.
A major healthcare hub with leading endocrinology centers, Mumbai coordinates access to advanced therapies like Crysvita for patients with XLH or TIO.
As part of the Delhi NCR region, the city has a strong concentration of endocrinology specialists, making it a key location for accessing rare metabolic bone disease treatments.
With a growing network of multispecialty hospitals, Bangalore supports access to Crysvita through structured import pathways guided by treating specialists.
Home to several reputed endocrinology practices, Chennai facilitates access to Crysvita for patients with X-linked hypophosphatemia.
A growing hub for specialty care, Hyderabad supports coordinated access to Crysvita for eligible patients under specialist supervision.
Eastern India's leading medical centers in Kolkata coordinate Crysvita access for patients with rare bone and mineral disorders.
With an expanding base of endocrinology clinics, Pune facilitates timely access to Crysvita under prescription.
Gujarat's leading hospitals support regulated access to Crysvita for eligible patients.
Kerala's healthcare network, including major hospitals in Kochi, coordinates access to advanced biologics like Crysvita.
Serving North India, Chandigarh's specialist centers facilitate access to Crysvita for patients from Punjab, Haryana, and Himachal Pradesh.
Rajasthan's leading hospitals support patient access to Crysvita through the Named Patient Program.
A key referral center for North India, Lucknow facilitates coordinated access to Crysvita under specialist care.
Odisha's growing specialty healthcare sector supports patient access to Crysvita.
As a referral hub for the North-East, Guwahati facilitates access to Crysvita for patients across the region.
Access can also be coordinated for patients in other major Indian cities, subject to a valid prescription and regulatory requirements.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 08 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 08 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
